IGMS — IGM Biosciences Income Statement
0.000.00%
Last trade - 00:00- $423.26m
- $85.59m
- $2.13m
Annual income statement for IGM Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 1.07 | 2.13 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 44.5 | 83.3 | 165 | 229 | 266 |
| Operating Profit | -44.5 | -83.3 | -165 | -228 | -263 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -43.1 | -81.4 | -165 | -221 | -246 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -43.1 | -81.4 | -165 | -221 | -246 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.1 | -81.4 | -165 | -221 | -246 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.1 | -81.4 | -165 | -221 | -246 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.41 | -2.65 | -4.93 | -5.32 | -4.71 |